If you are having trouble viewing this email, please view it on our website.

         
 
A Service Announcement from Pharmexec
  Applied Clinical Trials  
   
 
On the heels of Catalent’s acquisition of Aptuit's Clinical Trial Supplies business, Catalent invites you to review the results of a recent “double-blind” study, established market trends and take an exclusive look into clinical service industry changes. 
Much has been published about the general effects brought on by the consolidation of pharmaceutical companies, increased generic competition, growth in the biologics arena, and even the shift of clinical trial studies to regions outside the US. This presentation will explore these issues along with:
  • Independent research results and industry statistics
  • “Double-Blind” research summary results reflecting clinical specific industry trends
  • Data backed by the voice of global clinical managers
  • Required solutions to overcome the “timeline crunch”
  • Specific investments made by Catalent to meet these needs
Every molecule has a challenge. We have the solution.
Email: solutions@catalent.com
Call: +1 888 SOLUTION (7658846)
Visit:
www.catalent.com
Click below to learn interesting factoids about Catalent Clinical Supply Services and how we deliver on our brand promise of more products, better treatments, reliably supplied.
Catalent formally acquires Aptuit Clinical Trial Supplies Business, read the PR
Learn more about us by visiting our YouTube®
channel

Visit our resource center to download other offering info and brochures
or call +1-888-SOLUTION (7658846) to speak with one of our experts today!

To unsubscribe or manage your subscriptions, please click here.

For more information call +1-866-720-3148, Email us at marketing@catalent.com, or visit www.catalent.com.

Catalent Pharma Solutions respects your privacy.
©Copyright 2011, Catalent Pharma Solutions, 14 Schoolhouse Road, Somerset, NJ 08873. All rights reserved.
 

ACT is published by Advanstar Communications, 485 Rt 1 South, Iselin, NJ 08830.
This is an advertisement sent on behalf of this advertiser.